CRISPR Therapeutics AG Annual Return On Equity in % from 2017 to 2023

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
CRISPR Therapeutics AG quarterly/annual Return On Equity history and growth rate from 2017 to 2023.
  • CRISPR Therapeutics AG Return On Equity for the quarter ending September 30, 2024 was -12.2 %, a 37.5% increase year-over-year.
  • CRISPR Therapeutics AG annual Return On Equity for 2023 was -8.44 %, a 73.5% increase from 2022.
  • CRISPR Therapeutics AG annual Return On Equity for 2022 was -31.9 %, a 297% decline from 2021.
  • CRISPR Therapeutics AG annual Return On Equity for 2021 was 16.2 %.
Return On Equity, Annual (%)
Return On Equity, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2023 -8.44 +23.4 +73.5% Jan 1, 2023 Dec 31, 2023
2022 -31.9 -48.1 -297% Jan 1, 2022 Dec 31, 2022
2021 16.2 +45.3 Jan 1, 2021 Dec 31, 2021
2020 -29.1 -40.8 -347% Jan 1, 2020 Dec 31, 2020
2019 11.7 +60.1 Jan 1, 2019 Dec 31, 2019
2018 -48.4 -13.3 -37.9% Jan 1, 2018 Dec 31, 2018
2017 -35.1 Jan 1, 2017 Dec 31, 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.